RT Journal Article
SR Electronic
T1 A digital twin model incorporating generalized metabolic fluxes to predict chronic kidney disease in type 2 diabetes mellitus
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.09.22.23295944
DO 10.1101/2023.09.22.23295944
A1 Surian, Naveenah Udaya
A1 Batagov, Arsen
A1 Wu, Andrew
A1 Lai, Wen Bin
A1 Sun, Yan
A1 Bee, Yong Mong
A1 Dalan, Rinkoo
YR 2023
UL http://medrxiv.org/content/early/2023/09/24/2023.09.22.23295944.abstract
AB One of the biggest complication in diabetes patients is chronic kidney disease (CKD), making it a tremendous burden on the country’s public healthcare system. We have developed HealthVector Diabetes (HVD), a digital twin model that leverages generalized metabolic fluxes (GMF) to proficiently predict the onset of CKD and facilitate its early detection. Our HVD GMF model utilized commonly available clinical and physiological biomarkers as inputs for identification and prediction of CKD. We employed four diverse multi-ethnic cohorts (n=7072): one Singaporean cohort (EVAS, n=289) and one North American cohort (NHANES, n=1044) for baseline CKD identification, and two multi-center Singaporean cohorts (CDMD, n=2119 and SDR, n=3627) for 3-year CKD prediction. We developed one identification model and two prediction models (with complete or incomplete parameters). The identification model demonstrated strong performance with an AUC ranging from 0.80 to 0.82. For prediction, with incomplete parameters, we achieved an AUC of 0.75, while the complete parameter model achieved an improved AUC of 0.86. Our model also effectively stratifies patients into low, moderate, and high-risk categories, with the high-risk category having the highest proportion (53.3-62.9%) of patients with CKD. Our method also reveals metabolic health profile differences among patient subgroups at baseline, indicating that patient subgroups who develop future CKD exhibit more deteriorated profiles compared to future non-CKD patients. Furthermore, we also show that GMF-based clustering reveals distinct metabolic profile differences that act as drivers for CKD progression, and the distance between different patient clusters can be used to map patient health trajectories. Our HVD GMF digital twin model has the ability to identify patients with baseline CKD and predict future CKD within a 3-year time frame. Furthermore, our approach enables risk stratification, sub-grouping and clustering based on metabolic health profiles, positioning our model as a valuable clinical application tool for healthcare practitioners.Competing Interest StatementYMB, RD and SY have no specific conflict of interest with regards to this manuscript. AB and AW are the co-founders of Mesh Bio Pte. Ltd. and have filed patents related to this work. WL and NUS are employees of Mesh Bio Pte. Ltd.Funding StatementThe work was supported by Enterprise SG, under the Startup SGTech POC and POV grant and also by A*STAR, Singapore under its Industry Alignment Pre-Positioning Fund (Grant No. H19/01/a0/023 - Diabetes Clinic of the Future). RD is supported by Ministry of Health, Clinician Scientist Award (MOH-000014), Ng Teng Fong Foundation Grant and National Healthcare Group. The funding bodies played no role in the design of the study and collection, analysis, interpretation of data or in writing the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Singaporean (National Healthcare Group and SingHealth) Institutional Review Board gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe authors agree to make the data and materials supporting the results or analyses presented in their paper available upon reasonable request. Access to the Singapore Diabetes Registry data set or the other data sets is possible on reasonable request to the corresponding authors, under restrictions subject to obtaining ethics approval from institutional boards and an appropriate data-use and/or research agreement.